Zeptosens completes E9.1m financing

This second round will be used to develop the life science company’s products.

TVM Techno Venture Management has led an E9.1m second round of financing for Zeptosens, a life sciences company. Swiss Life Private Equity Partners, the private equity arm of Swiss Life and several private investors also participated in the round.

The capital raised will be used to accelerate the company’s development and production program for its life science projects. These include an ultra-sensitive, proprietary microarray readout system called ZeptoREADER and the ZeptoMARK protein microarray product family.

The Swiss firm focuses on bioanalytical solutions. The company was founded in September 1998 by a team of life science analysts from Novartis Pharma AG. The team had invented a unique bioaffinity interaction analysis system which was licensed exclusively by Novartis to Zeptosens for applications outside the diagnosis of human and veterinary health.

Dr. Markus Ehrat, chief executive of Zeptosens said: “We are delighted to have this outstanding group of investors participate in Zeptosens' financing. This is a valuable recognition of the company's remarkable progress over the short time period since its start of operations in March 1999.”

Dr. Alexandra Goll, a partner at TVM who joins Zeptosens’ board of directors, said: “We see an enormous potential for Zeptosens' nanotechnology-based approach to microarrays and detection systems. This approach combined with a strong and visionary management team has convinced us to participate in the company.”